Tom 15, Nr 3 (2020)
Sprawozdanie z konferencji / Sprawozdanie
Opublikowany online: 2020-03-28
Wyświetlenia strony
321
Wyświetlenia/pobrania artykułu
405
Najnowsze wyniki badań klinicznych z Kongresu Europejskiego Towarzystwa Kardiologicznego w Paryżu, 31 sierpnia–4 września 2019
DOI: 10.5603/FC.2020.0037
Folia Cardiologica 2020;15(3):272-275.
Streszczenie
Brak
Słowa kluczowe: DAPA HFPARAGON HFISAR REACT 5THEMISAFIRE
Referencje
- McMurray JJV, Solomon SD, Inzucchi SE, et al. DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019; 381(21): 1995–2008.
- Solomon SD, McMurray JJV, Solomon SD, et al. PARAGON-HF Steering Committee and Investigators, PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019; 381(17): 1609–1620.
- Schüpke S, Neumann FJ, Menichelli M, et al. ISAR-REACT 5 Trial Investigators. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med. 2019; 381(16): 1524–1534.
- Steg PG, Bhatt DL, Simon T, et al. THEMIS Steering Committee and Investigators. Ticagrelor in patients with stable coronary disease and diabetes. N Engl J Med. 2019; 381(14): 1309–1320.
- Bhatt DL, Steg PG, Mehta SR, et al. THEMIS Steering Committee and Investigators. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet. 2019; 394(10204): 1169–1180.
- Yasuda S, Kaikita K, Akao M, et al. AFIRE Investigators. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med. 2019; 381(12): 1103–1113.
